Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MBZJF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
YL205
|
|||||
| Synonyms |
YL205
Click to Show/Hide
|
|||||
| Organization |
MediLink Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-NaPi2b mAb
|
Antibody Info | ||||
| Antigen Name |
Sodium-dependent phosphate transport protein 2B (SLC34A2)
|
Antigen Info | ||||
| Payload Name |
YL0010014
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
VK*G-NHCH2-O linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
pelitecan
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Endometrial cancer |
2 Trials
|
|||||||||
| Kidney cancer |
2 Trials
|
|||||||||
| Lung cancer |
2 Trials
|
|||||||||
| Ovarian cancer |
2 Trials
|
|||||||||
| Unspecific solid tumor |
2 Trials
|
ADC-specific functional property(2027 Update)
Bystander Killing Effect
| Bystander Killing Effect | Description | Reference |
|---|---|---|
| yes |
Additionally, YL205 exhibited strong potency, high internalization, potent cytotoxicity and bystander-mediated cell killing toward tumor cells.
|
[1]
|
References